| Cheryl Renee Blanchard |
Cheryl Renee Blanchard is currently the President, Chief Executive Officer & Director at Anika Therapeutics, Inc. She is also a Director at Massachusetts Biotechnology Council, Elute, Inc., Daré Bioscience, Inc., and Vigil Neuroscience, Inc. Additionally, she is a Member of the National Academy of Engineering and a Professor at the University of Texas at San Antonio. In her former positions, Dr. Blanchard served as the President, Chief Executive Officer & Director at Microchips Biotech, Inc. from 2014 to 2019. She was also the President & Chief Executive Officer at Keratin Biosciences, Inc. from 2018 to 2019. Furthermore, she worked as a Director at Neuronetics, Inc. from 2019 to 2020. She has also held positions as a Director at Novum Medical, Inc., Independent Director at SeaSpine Holdings Corp., and Chief Scientific Officer at Zimmer Biomet Holdings, Inc. from 2000 to 2011. Dr. Blanchard's education includes a graduate and doctorate degree from The University of Texas at Austin and an undergraduate degree from Alfred University. |
| Anne Nunes |
Anne Nunes is currently the Chief Operating Officer & Senior Vice President at Anika Therapeutics, Inc. She previously worked as the Head of Research & Development at Eli Lilly & Co. and as the Senior Vice President of Global Operations at Smith & Nephew plc. Ms. Nunes holds an MBA from Questrom School of Business and an undergraduate degree from the University of Illinois At Urbana–Champaign. |
| Steven W. Ek |
Steven W. Ek was the founder of ArthroSurface, Inc. founded in 2002, where he held the titles of President, Chief Executive Officer & Director from 2013 to 2015. Currently, he is the Vice President-Research & Development at Anika Therapeutics, Inc. since 2020. Previously, he worked as Director-Research & Development at Smith & Nephew Endoscopy, Inc., Head-Research & Development at CONMED Corp., Design Engineer at Linvatec Corp., and Vice President-Engineering at Primo Medical Group, Inc. Mr. Ek completed his undergraduate degree from the University of Florida. |
| Dawn J. Wilson |
Dawn J. Wilson is currently the Vice President-Research & Development at Anika Therapeutics, Inc. She previously worked as the Director-Quality Assurance & Control at Salient Surgical Technologies, Inc., the Principal at United States Surgical Corp., and the Vice President-Quality & Regulatory at ArthroSurface, Inc. Ms. Wilson completed her undergraduate degree at Boston University and her graduate degree at the University of Bridgeport. |
| Jeffery S. Thompson |
Jeffery S. Thompson founded Agema Technology in 2012, where he is working as President from 2012. Mr. Thompson also currently works at Anika Therapeutics, Inc., as Independent Director from 2024, Infinity Home Care LLC, as Director, LifeSync Corp., as Director from 2008, Westone Laboratories, Inc., as Director, The Columbus Group, Inc., as Director, Formulated Solutions LLC, as Director, Medical Neurogenetics LLC, as Director, Columbus Organization Holdings LLC, as Director, Spectrum Medical Partners, Inc., as Director, Itrac LLC, as Director, Legacy-Xspire Holdings LLC, as Director from 2008, Healthcare Products Holdings, Inc., as Partner, and HealthEdge Investment Partners, LLC, as Partner from 2012. Mr. Thompson also formerly worked at Advanced Bio-Technologies, Inc., as Chairman, President & Chief Executive Officer from 2008 to 2017, Enaltus LLC, as Chairman, President & Chief Executive Officer from 2008 to 2017, Woodbury Health Products, Inc., as Chairman, Data Dimensions LLC, as Director, Stiefel Laboratories, Inc. (New York), as Chief Operating Officer & Director from 2003 to 2008, Sinclair Pharma Ltd., as Independent Non-Executive Director from 2014 to 2018, Santus LLC, as Director, Smithkline Beecham Plc, as Principal, Bausch & Lomb Pharmaceuticals, Inc., as Principal, and Glades Pharmaceuticals LLC, as President from 1994 to 2006. Mr. Thompson received his undergraduate degree in 1990 from the University of Pittsburgh. |
| Ian McLeod |
Ian McLeod is currently the Chief Accounting Officer & Vice President at Anika Therapeutics, Inc. He previously worked as a Controller at ABIOMED, Inc. from 2007 to 2017 and as a Corporate Controller at Idenix Pharmaceuticals LLC from 2004 to 2007. Mr. McLeod has an undergraduate degree from the University of Western Ontario and an MBA from McMaster University. |
| Michael L. Levitz |
Michael L. Levitz currently works at Anika Therapeutics, Inc., as Chief Financial Officer, Treasurer & EVP from 2020. Mr. Levitz also formerly worked at Ultrasonix Medical Corp., as Director, Analogic Corp., as Chief Financial Officer, Treasurer & Senior VP from 2011 to 2015, Hologic, Inc., as Vice President & Controller-Cytyc Business Unit in 2009, Cytyc Corp., as Vice President & Controller in 2007, NEON Communications, Inc., as Controller in 2002, Arthur Andersen LLP, as Audit Manager in 2000, and Insulet Corp., as Treasurer, CFO & Principal Accounting Officer from 2015 to 2019. Mr. Levitz received his undergraduate degree from the University of California, Santa Barbara. |
| John B. Henneman |
Mr. John B. Henneman, III, is an Independent Director at Orthofix Medical, Inc., a Chairman at Anika Therapeutics, Inc., a Lead Independent Director at Aprea Therapeutics, Inc. and a Lead Independent Director at R1 RCM, Inc. He is on the Board of Directors at Orthofix Medical, Inc., Aprea Therapeutics AB, Aprea Therapeutics, Inc., R1 RCM, Inc. and Alafair Biosciences, Inc. Mr. Henneman was previously employed as an Independent Director by SeaSpine Holdings Corp., a Chief Financial Officer, Secretary & Executive VP by NewLink Genetics Corp., a Chief Financial Officer by Integra LifeSciences Holdings Corp., an Interim Co-Chief Executive Officer & Secretary by Neuromedical Systems, Inc., and a Chairman by New Deal Technology SAS. He received his undergraduate degree from Princeton University and a graduate degree from The University of Michigan Law School. |
| Mira Leiwant |
Mira Leiwant is currently the VP-Quality, Regulatory & Clinical Affairs at Anika Therapeutics, Inc. She previously worked as the Senior Director-Regulatory & Quality Engineering at LifeCell Corp. and as the Vice President-Regulatory Affairs at BTG International, Inc. She received her undergraduate and graduate degrees from Cornell University in 1997 and 1998, respectively. |
| Stephen O. Richard |
Stephen O. Richard's current job(s) include serving as an Independent Director at Anika Therapeutics, Inc. since 2020, and as the Chief Risk Officer & Senior Vice President at Becton, Dickinson & Co. since 2016. He is also a Member of the Executive Leadership Council, Inc. and Kappa Alpha PSI Fraternity, Inc.Mr. Richard's former job(s) include serving as a Director-Regional Audit at Citigroup, Inc., Director at the New Jersey Society of Certified Public Accountants, and Senior Manager at Deloitte & Touche LLP. He also served as the Chief Executive & Financial Officer at the National Basketball Association, Inc. from 2010 to 2013, and as the Senior VP-Global Operations & Business Development at NBA Properties, Inc. from 2013 to 2016. Additionally, he worked as a District Manager-Financial Planning & Analysis at AT&T Corp. and as the Chief Executive & Financial Officer at NBA China from 2010 to 2013. Mr. Richard's education includes an undergraduate degree from Northeastern University and an MBA from Columbia Business School. |
| Gary P. Fischetti |
Gary P. Fischetti is currently the Chairman of Orchid Orthopedic Solutions LLC and a Director at Extremity Medical LLC, Anika Therapeutics, Inc., and Acuitive Technologies, Inc. He previously served as the Group Chairman-North American Medical Devices at Johnson & Johnson, Chairman at DePuy Orthopaedics, Inc., President at DePuy Spine, Inc., and Independent Director at ConforMIS, Inc. Fischetti holds an MBA from Rutgers State University of New Jersey and an undergraduate degree from Villanova University. |
| Glenn R. Larsen |
Glenn R. Larsen is the founder of Aquinnah Pharmaceuticals, Inc. (founded in 2014) and 180 Therapeutics LP (founded in 2013), where he holds the titles of Chairman, President & Chief Executive Officer and Chairman, respectively. Currently, he is an Independent Director at Anika Therapeutics, Inc. (since 2015). Previously, he held Senior Director positions at Genetics Institute LLC (2003-2010) and COO, Director & Executive VP-Development positions at Hydra Biosciences, Inc. (2003-2010). He was also a Vice President at Wyeth Pharmaceuticals LLC. From 2010 to 2013, he was the CSO, Executive VP-Research & Development at SpringLeaf Therapeutics, Inc. Dr. Larsen holds a doctorate degree from Stony Brook University. |
| Sheryl L. Conley |
Sheryl L. Conley is an Independent Director at Anika Therapeutics, Inc. since 2021, a Director at Orthopedics Capital Foundation, Inc. since 2012, and an Independent Director at Neuronetics, Inc. since 2019. Previously, she served as the President & Chief Executive Officer at Orthoworx from 2012 to 2017, the Non-Executive Chairman at Surgalign Holdings, Inc. from 2021 to 2023, the President & Director at AcceLINX, Inc. from 2017 to 2022, and the Chief Marketing Officer at Zimmer Biomet Holdings, Inc. from 2000 to 2008. She also held the position of Chief Marketing Officer at Zimmer, Inc. from 2005 to 2008. Ms. Conley obtained her undergraduate degree and MBA from Ball State University (Indiana). |
| Susan L. N. Vogt |
Susan L. N. Vogt is an Independent Director at Anika Therapeutics, Inc., Non-Executive Director at TAP Biosystems Ltd., and Director at Sharps Compliance, Inc. She was previously the President, Chief Executive Officer & Director at SeraCare Life Sciences, Inc., Chief Executive Officer & Director at Aushon Biosystems, Inc., Independent Director at Sharps Compliance Corp., Director at Justrite Manufacturing Co. LLC, Independent Non-Executive Director at Andor Technology Ltd., and President-Bio Pharmaceutical Division at EMD Millipore Corp. She holds an undergraduate degree from Brown University and an MBA from Boston University. |
